Aligos Therapeutics Expands Collaboration Deal With Merck
12 January 2022 - 1:52AM
Dow Jones News
By Chris Wack
Aligos Therapeutics Inc. said it has expanded its ongoing
collaboration agreement with Merck to discover and develop
oligonucleotide therapies for non-alcoholic steatohepatitis.
Under the original agreement, Merck and Aligos committed to
applying Aligos' oligonucleotide platform technology to discover,
research, optimize and develop oligonucleotides directed against a
certain undisclosed non-alcoholic steatohepatitis target and up to
one additional target of interest in the cardiometabolic/fibrosis
space.
That agreement has now been expanded to include the in-license
by Merck of an early-stage program with respect to a second
undisclosed NASH target on which Aligos has previously been working
independently and separately from Merck. In addition, under this
expanded arrangement, Merck has the ability of adding an additional
third target of interest in the cardiometabolic/fibrosis space to
the collaboration.
Under the expanded agreement, Aligos will receive a payment from
Merck for the in-license of the program directed at a second
undisclosed NASH target. Aligos will also receive an additional
payment upon designation of a third target for the
collaboration.
With respect to each target in the collaboration, Aligos will be
eligible to receive up to $460 million in development and
commercialization milestones as well as tiered royalties on sales.
Aligos is primarily responsible for designing, synthesizing and
evaluating the oligonucleotide candidates and delivering optimized
lead molecules. Thereafter, Merck is responsible for subsequent
research, clinical development and commercialization.
Aligos shares were up 11% to $4.12 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 11, 2022 09:37 ET (14:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2023 to Apr 2024